Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that an injectable hydrogel based on platelet-rich plasma and laponite improved wound healing in diabetic and normal rats by enhancing angiogenesis and macrophage polarization.

This article reviews literature on hair casts, shedding light on this rarely discussed hair disorder, along with a case report of a 5-year-old mistakenly treated for head lice.

In this review, platelet concentrates were found to show comparable efficacy to steroids and immunosuppressive drugs in treating oral lichen planus, with some studies reporting more benefits and others noting more severe adverse reactions with platelet treatments.

A 70-year-old woman with a rare skin condition improved after treatment with topical steroids and acitretin.

This article discusses recent findings on piedra infections in hair and their keratinolytic activities, but reports no new clinical results.

In this laboratory study, researchers developed a genipin-stabilized asymmetric PLA/gelatin scaffold that mimics skin architecture, supports fibroblast proliferation, and closes scratches effectively, suggesting its potential for epidermal-dermal regeneration and applications in sensing or drug delivery.

In this study, ritlecitinib was generally well tolerated in pediatric alopecia areata patients aged 6 to <12 years, with no severe or serious adverse events reported, and the drug's pharmacokinetic parameters were successfully characterized.

This study reports that RU 58841-myristate, a new antiandrogen prodrug formulated with solid lipid nanoparticles, shows potential for targeting hair follicles in preclinical laboratory settings.

This study found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg for treating severe alopecia areata at Weeks 24 and 52, potentially influencing reimbursement decisions.

This study reported that ritlecitinib 50 mg and baricitinib 4 mg showed similar efficacy in treating severe alopecia areata, with no significant difference in hair regrowth outcomes at Week 24, but there remains considerable uncertainty and a need for further research.

This review highlights Ritlecitinib as a promising new oral treatment for Alopecia Areata, emphasizing its targeted action and potential efficacy, especially in adults and adolescents, though it notes the need for further real-world effectiveness and long-term safety studies.

In this study, a bioengineered construct using a biodegradable polycaprolactone mat cocultured with human keratinocyte and rabbit dermal fibroblast cells demonstrated potential as a tissue-engineered skin substitute, showing good cell adhesion and growth.

This report presents a case of pili torti in a young girl with citrullinemia, a novel association not previously documented.

The girl's "dandruff" was actually harmless hair casts, not a hygiene issue.

This study found that ritlecitinib, approved for alopecia areata in patients aged 12 and older, has an acceptable safety profile with mild to moderate side effects and no increase in serious adverse events compared to placebo.

This study describes characteristics and outcomes for adults initiating ritlecitinib for severe alopecia areata, highlighting increased hair regrowth and physician satisfaction with longer treatment durations, despite ongoing psychosocial impacts like embarrassment and anxiety among patients.

This study found that ritlecitinib was well tolerated in children aged 6 to under 12 years with severe alopecia areata, with ongoing trials examining its efficacy and safety over a 24-week period and in long-term use up to 36 months.

Lamotrigine can cause hair loss in some patients.

This review discusses the potential of lecithin organogels for improving topical drug delivery and presents no new experimental results; the authors highlight their stability and low skin irritancy as advantages.

Results are not reported in this article by Zizhuo Li et al. on baricitinib as a treatment for lichen planopilaris.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

This study describes a method to create keratin hydrogels with adjustable erosion rates by mixing different ratios of keratose and kerateine, enabling controlled release of therapeutic agents like insulin-like growth factor 1.

This article describes a rare case of mixed black and white piedra in a patient's scalp hair, which is unusual as these two types of piedra rarely occur together.

This study found that treatment with ritlecitinib improved hair regrowth in alopecia areata patients, with many achieving significant results after 24 weeks compared to placebo.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

This study reported a rare case of pityriasis rubra pilaris-like skin reaction in an 18-year-old woman after starting ponatinib treatment for relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia, which resolved after treatment adjustment and did not recur over 15 months.

This report describes two cases of white piedra caused by Trichosporon inkin in a northern climate, detailing clinical findings and diagnosis without presenting new experimental results.

In this phase 2b/3 trial, ritlecitinib showed effectiveness in treating alopecia areata patients with varying hair loss profiles, significantly improving patient-reported outcomes for hair regrowth and satisfaction compared to placebo, regardless of the hair loss type and extent at baseline.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.